Therapy for localized Ewing's sarcoma of bone
Fifty-two previously untreated patients with localized Ewing's sarcoma of bone were treated with nonintensive chemotherapy in combination with surgery or radiation therapy (RT). RT was delivered to limited volumes in a dose dependent on the initial response to induction chemotherapy (30 to 35 G...
Gespeichert in:
Veröffentlicht in: | Journal of clinical oncology 1989-02, Vol.7 (2), p.208-213 |
---|---|
Hauptverfasser: | , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 213 |
---|---|
container_issue | 2 |
container_start_page | 208 |
container_title | Journal of clinical oncology |
container_volume | 7 |
creator | Hayes, F A Thompson, E I Meyer, W H Kun, L Parham, D Rao, B Kumar, M Hancock, M Parvey, L Magill, L |
description | Fifty-two previously untreated patients with localized Ewing's sarcoma of bone were treated with nonintensive chemotherapy in combination with surgery or radiation therapy (RT). RT was delivered to limited volumes in a dose dependent on the initial response to induction chemotherapy (30 to 35 Gy v 50 to 55 Gy). Fifty of the 52 patients achieved complete or partial responses with induction chemotherapy, with one nonresponding patient rendered free of tumor with surgery. Fifty patients were evaluable for local control of tumor and overall response to protocol therapy. Seventeen relapses have occurred; three metastatic, four local plus metastatic, and ten local. Two factors predicted worse disease-free survival: high WBC count (P = .03) and size of primary tumor (P = .05). Of the 14 local recurrences, 12 occurred in 28 patients who presented with primary tumors greater than 8 cm in size while only two of 22 patients with lesions less than 8 cm had local recurrence. The Kaplan-Meier estimate of disease-free survival at 3 years is 82% for those with small lesions and 64% for those with larger lesions. Site of primary was of no prognostic value (P = .27). The 5-year survival estimate for all patients is 80% (median time on study, 3.3 years). |
doi_str_mv | 10.1200/JCO.1989.7.2.208 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_15561583</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>15561583</sourcerecordid><originalsourceid>FETCH-LOGICAL-c354t-1946c0bb98222304d61382d81052dbf2d988994bcfd05b6c39e2640a6f3e7e863</originalsourceid><addsrcrecordid>eNo9kD1PwzAYhC0EKqWwsyBlQDAl2K9jxx5RVb5UqUuR2CzHsdtUSV3sRlX59aRqYbrhnrvhQeiW4IwAxk8f41lGpJBZkUEGWJyhIWFQpEXB2Dka4oJCSgT9ukRXMa4wJrmgbIAGIHuM8iFK50sb9GafOB-Sxhvd1D-2Sia7er14jEnUwfhWJ94lpV_ba3ThdBPtzSlH6PNlMh-_pdPZ6_v4eZoayvJtSmTODS5LKQCA4rzihAqoBMEMqtJBJYWQMi-NqzAruaHSAs-x5o7awgpOR-jh-LsJ_ruzcavaOhrbNHptfRcVYYwTJmgP4iNogo8xWKc2oW512CuC1cGQ6g2pgyFVKFC9oX5yd_ruytZW_4OTkr6_P_bLerHc1cGq2Oqm6WlQK-P_bn4BAZhruA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>15561583</pqid></control><display><type>article</type><title>Therapy for localized Ewing's sarcoma of bone</title><source>MEDLINE</source><source>American Society of Clinical Oncology Journals</source><source>Journals@Ovid Complete</source><creator>Hayes, F A ; Thompson, E I ; Meyer, W H ; Kun, L ; Parham, D ; Rao, B ; Kumar, M ; Hancock, M ; Parvey, L ; Magill, L</creator><creatorcontrib>Hayes, F A ; Thompson, E I ; Meyer, W H ; Kun, L ; Parham, D ; Rao, B ; Kumar, M ; Hancock, M ; Parvey, L ; Magill, L</creatorcontrib><description>Fifty-two previously untreated patients with localized Ewing's sarcoma of bone were treated with nonintensive chemotherapy in combination with surgery or radiation therapy (RT). RT was delivered to limited volumes in a dose dependent on the initial response to induction chemotherapy (30 to 35 Gy v 50 to 55 Gy). Fifty of the 52 patients achieved complete or partial responses with induction chemotherapy, with one nonresponding patient rendered free of tumor with surgery. Fifty patients were evaluable for local control of tumor and overall response to protocol therapy. Seventeen relapses have occurred; three metastatic, four local plus metastatic, and ten local. Two factors predicted worse disease-free survival: high WBC count (P = .03) and size of primary tumor (P = .05). Of the 14 local recurrences, 12 occurred in 28 patients who presented with primary tumors greater than 8 cm in size while only two of 22 patients with lesions less than 8 cm had local recurrence. The Kaplan-Meier estimate of disease-free survival at 3 years is 82% for those with small lesions and 64% for those with larger lesions. Site of primary was of no prognostic value (P = .27). The 5-year survival estimate for all patients is 80% (median time on study, 3.3 years).</description><identifier>ISSN: 0732-183X</identifier><identifier>EISSN: 1527-7755</identifier><identifier>DOI: 10.1200/JCO.1989.7.2.208</identifier><identifier>PMID: 2915236</identifier><language>eng</language><publisher>United States: American Society of Clinical Oncology</publisher><subject>Adolescent ; Adult ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Bone Neoplasms - pathology ; Bone Neoplasms - therapy ; Child ; Child, Preschool ; Combined Modality Therapy ; Female ; Humans ; Male ; Neoplasm Recurrence, Local ; Patient Compliance ; Prognosis ; Remission Induction ; Risk Factors ; Sarcoma, Ewing - pathology ; Sarcoma, Ewing - secondary ; Sarcoma, Ewing - therapy</subject><ispartof>Journal of clinical oncology, 1989-02, Vol.7 (2), p.208-213</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c354t-1946c0bb98222304d61382d81052dbf2d988994bcfd05b6c39e2640a6f3e7e863</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,3729,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/2915236$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hayes, F A</creatorcontrib><creatorcontrib>Thompson, E I</creatorcontrib><creatorcontrib>Meyer, W H</creatorcontrib><creatorcontrib>Kun, L</creatorcontrib><creatorcontrib>Parham, D</creatorcontrib><creatorcontrib>Rao, B</creatorcontrib><creatorcontrib>Kumar, M</creatorcontrib><creatorcontrib>Hancock, M</creatorcontrib><creatorcontrib>Parvey, L</creatorcontrib><creatorcontrib>Magill, L</creatorcontrib><title>Therapy for localized Ewing's sarcoma of bone</title><title>Journal of clinical oncology</title><addtitle>J Clin Oncol</addtitle><description>Fifty-two previously untreated patients with localized Ewing's sarcoma of bone were treated with nonintensive chemotherapy in combination with surgery or radiation therapy (RT). RT was delivered to limited volumes in a dose dependent on the initial response to induction chemotherapy (30 to 35 Gy v 50 to 55 Gy). Fifty of the 52 patients achieved complete or partial responses with induction chemotherapy, with one nonresponding patient rendered free of tumor with surgery. Fifty patients were evaluable for local control of tumor and overall response to protocol therapy. Seventeen relapses have occurred; three metastatic, four local plus metastatic, and ten local. Two factors predicted worse disease-free survival: high WBC count (P = .03) and size of primary tumor (P = .05). Of the 14 local recurrences, 12 occurred in 28 patients who presented with primary tumors greater than 8 cm in size while only two of 22 patients with lesions less than 8 cm had local recurrence. The Kaplan-Meier estimate of disease-free survival at 3 years is 82% for those with small lesions and 64% for those with larger lesions. Site of primary was of no prognostic value (P = .27). The 5-year survival estimate for all patients is 80% (median time on study, 3.3 years).</description><subject>Adolescent</subject><subject>Adult</subject><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Bone Neoplasms - pathology</subject><subject>Bone Neoplasms - therapy</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Combined Modality Therapy</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Neoplasm Recurrence, Local</subject><subject>Patient Compliance</subject><subject>Prognosis</subject><subject>Remission Induction</subject><subject>Risk Factors</subject><subject>Sarcoma, Ewing - pathology</subject><subject>Sarcoma, Ewing - secondary</subject><subject>Sarcoma, Ewing - therapy</subject><issn>0732-183X</issn><issn>1527-7755</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1989</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kD1PwzAYhC0EKqWwsyBlQDAl2K9jxx5RVb5UqUuR2CzHsdtUSV3sRlX59aRqYbrhnrvhQeiW4IwAxk8f41lGpJBZkUEGWJyhIWFQpEXB2Dka4oJCSgT9ukRXMa4wJrmgbIAGIHuM8iFK50sb9GafOB-Sxhvd1D-2Sia7er14jEnUwfhWJ94lpV_ba3ThdBPtzSlH6PNlMh-_pdPZ6_v4eZoayvJtSmTODS5LKQCA4rzihAqoBMEMqtJBJYWQMi-NqzAruaHSAs-x5o7awgpOR-jh-LsJ_ruzcavaOhrbNHptfRcVYYwTJmgP4iNogo8xWKc2oW512CuC1cGQ6g2pgyFVKFC9oX5yd_ruytZW_4OTkr6_P_bLerHc1cGq2Oqm6WlQK-P_bn4BAZhruA</recordid><startdate>19890201</startdate><enddate>19890201</enddate><creator>Hayes, F A</creator><creator>Thompson, E I</creator><creator>Meyer, W H</creator><creator>Kun, L</creator><creator>Parham, D</creator><creator>Rao, B</creator><creator>Kumar, M</creator><creator>Hancock, M</creator><creator>Parvey, L</creator><creator>Magill, L</creator><general>American Society of Clinical Oncology</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope></search><sort><creationdate>19890201</creationdate><title>Therapy for localized Ewing's sarcoma of bone</title><author>Hayes, F A ; Thompson, E I ; Meyer, W H ; Kun, L ; Parham, D ; Rao, B ; Kumar, M ; Hancock, M ; Parvey, L ; Magill, L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c354t-1946c0bb98222304d61382d81052dbf2d988994bcfd05b6c39e2640a6f3e7e863</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1989</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Antineoplastic Combined Chemotherapy Protocols - adverse effects</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Bone Neoplasms - pathology</topic><topic>Bone Neoplasms - therapy</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Combined Modality Therapy</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Neoplasm Recurrence, Local</topic><topic>Patient Compliance</topic><topic>Prognosis</topic><topic>Remission Induction</topic><topic>Risk Factors</topic><topic>Sarcoma, Ewing - pathology</topic><topic>Sarcoma, Ewing - secondary</topic><topic>Sarcoma, Ewing - therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hayes, F A</creatorcontrib><creatorcontrib>Thompson, E I</creatorcontrib><creatorcontrib>Meyer, W H</creatorcontrib><creatorcontrib>Kun, L</creatorcontrib><creatorcontrib>Parham, D</creatorcontrib><creatorcontrib>Rao, B</creatorcontrib><creatorcontrib>Kumar, M</creatorcontrib><creatorcontrib>Hancock, M</creatorcontrib><creatorcontrib>Parvey, L</creatorcontrib><creatorcontrib>Magill, L</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><jtitle>Journal of clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hayes, F A</au><au>Thompson, E I</au><au>Meyer, W H</au><au>Kun, L</au><au>Parham, D</au><au>Rao, B</au><au>Kumar, M</au><au>Hancock, M</au><au>Parvey, L</au><au>Magill, L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Therapy for localized Ewing's sarcoma of bone</atitle><jtitle>Journal of clinical oncology</jtitle><addtitle>J Clin Oncol</addtitle><date>1989-02-01</date><risdate>1989</risdate><volume>7</volume><issue>2</issue><spage>208</spage><epage>213</epage><pages>208-213</pages><issn>0732-183X</issn><eissn>1527-7755</eissn><abstract>Fifty-two previously untreated patients with localized Ewing's sarcoma of bone were treated with nonintensive chemotherapy in combination with surgery or radiation therapy (RT). RT was delivered to limited volumes in a dose dependent on the initial response to induction chemotherapy (30 to 35 Gy v 50 to 55 Gy). Fifty of the 52 patients achieved complete or partial responses with induction chemotherapy, with one nonresponding patient rendered free of tumor with surgery. Fifty patients were evaluable for local control of tumor and overall response to protocol therapy. Seventeen relapses have occurred; three metastatic, four local plus metastatic, and ten local. Two factors predicted worse disease-free survival: high WBC count (P = .03) and size of primary tumor (P = .05). Of the 14 local recurrences, 12 occurred in 28 patients who presented with primary tumors greater than 8 cm in size while only two of 22 patients with lesions less than 8 cm had local recurrence. The Kaplan-Meier estimate of disease-free survival at 3 years is 82% for those with small lesions and 64% for those with larger lesions. Site of primary was of no prognostic value (P = .27). The 5-year survival estimate for all patients is 80% (median time on study, 3.3 years).</abstract><cop>United States</cop><pub>American Society of Clinical Oncology</pub><pmid>2915236</pmid><doi>10.1200/JCO.1989.7.2.208</doi><tpages>6</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0732-183X |
ispartof | Journal of clinical oncology, 1989-02, Vol.7 (2), p.208-213 |
issn | 0732-183X 1527-7755 |
language | eng |
recordid | cdi_proquest_miscellaneous_15561583 |
source | MEDLINE; American Society of Clinical Oncology Journals; Journals@Ovid Complete |
subjects | Adolescent Adult Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Bone Neoplasms - pathology Bone Neoplasms - therapy Child Child, Preschool Combined Modality Therapy Female Humans Male Neoplasm Recurrence, Local Patient Compliance Prognosis Remission Induction Risk Factors Sarcoma, Ewing - pathology Sarcoma, Ewing - secondary Sarcoma, Ewing - therapy |
title | Therapy for localized Ewing's sarcoma of bone |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-30T23%3A51%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Therapy%20for%20localized%20Ewing's%20sarcoma%20of%20bone&rft.jtitle=Journal%20of%20clinical%20oncology&rft.au=Hayes,%20F%20A&rft.date=1989-02-01&rft.volume=7&rft.issue=2&rft.spage=208&rft.epage=213&rft.pages=208-213&rft.issn=0732-183X&rft.eissn=1527-7755&rft_id=info:doi/10.1200/JCO.1989.7.2.208&rft_dat=%3Cproquest_cross%3E15561583%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=15561583&rft_id=info:pmid/2915236&rfr_iscdi=true |